This summary is generated by an algorithm. If you find any mistakes, let us know.

Biotechnology Health Care Health Diagnostics North America Therapeutics

Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline

– Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the successful closing of a $95m Series C financing.
– Proceeds from the financing will be used to advance Xilio’s lead therapeutic candidates, XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4 mAb), into clinical trials.
– Investigational new drug (IND) applications for XTX202 and XTX101 are expected to be filed with the U.S. Food and Drug Administration (FDA) in 2021.
– The financing was led by Rock Springs Capital and was joined by Bain Capital Life Sciences, Deerfield Management Company and RA Capital Management, among other new investors.

Source
Biotechnology Health Care North America Therapeutics

Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs

– Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced the completion of a $135 million Series C financing.
– The round was co-led by new investors, Logos Capital and Boxer Capital of Tavistock Group.
– Additional new investors in the raise include SoftBank Investment Advisers, Avoro Capital Advisors, funds and accounts managed by BlackRock, RA Capital Management, funds and accounts advised by T. Rowe Price Associates, Inc., Surveyor Capital (a Citadel company), Woodline Partners LP, Acuta Capital and Driehaus Capital Management, alongside existing investors ARCH Venture Partners, BVF Partners L.P., Casdin Capital, Mubadala Capital, Nextech Invest and Versant Ventures.

Source
Biotechnology North America

Asalyxa Bio Closes Seed Financing to Advance Lead Program into First-in-Human Clinical Studies

– Asalyxa Bio closed a $2m seed financing round to advance its lead program into first-in-human clinical trials.
– The financing was led by Research Bridge Partners, co-led by ID Ventures, and also included Michigan Rise Pre-Seed Fund III, BRCC of Western Michigan University, Ann Arbor Spark, Woodward Angels and other undisclosed investors.
– Proceeds from the financing will be used to advance Asalyxa Bio’s lead development candidate, ASX-100, into first-in-human clinical trials.
– Asalyxa Bio’s drug development programs are based on the company’s proprietary PANTHER technology platform, which enables the targeted delivery of therapeutic compounds directly to neutrophils and other key immune cells.

Source
Biotechnology North America

Florica Therapeutics, Inc. Awarded Competitive Grant from the National Science Foundation to Study Brain-Immune Axis in COVID-19

– Florica Therapeutics has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $255,678 to work on the Hypothalamus Stem Cell Exosomes for Treatment of COVID-19 project.
– The hypothalamus is crucial to secretion of cortisol and other immune-modulators that dampen the immune response following immune activation.
– Florica Therapeutics is a labor of love dedicated to my mother Florica Ichim.
– When I was 10 years old, my mother was diagnosed with leukemia. I promised her that she would not fight alone, I dedicated my life to extending the lives of others through biomedical research.

Source
Bioinformatics Biotechnology Genetics North America

Phase Genomics to Develop Commercial Platform for the Discovery of New Viruses with $1.7 Million Grant

– Phase Genomics, Inc. announced the receipt of a $1.7MM grant from the National Institute of Allergy and Infectious Diseases (NIAID).
– This funding will fuel the commercialization of a first-in-class solution for the discovery of DNA viruses, employing a novel reagent kit and robust software platform that leverages Phase Genomics’ proprietary Hi-C technology.
Phase Genomics is also funded by revenue from sales of its proximity ligation (Hi-C) kits, scientific services, and computational analysis.

Source
Asia Biotechnology Clinical Trials Health Care Pharmaceutical

Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing

– Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases, today announced the completion of an oversubscribed $230 million Series C financing.
– This financing round brings Clover’s total capital raised in the last 12 months to over $400 million (over RMB 2.5 billion).
– The Series C round was co-led by GL Ventures and Temasek, with participation from Oceanpine Capital, OrbiMed and existing investor Delos Capital.
– The proceeds will support the continued development and expansion of Clover’s pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag© technology platform.

Source
Asia Biotechnology Emergency Medicine Pharmaceutical

AnchorDx Completes USD 40 Million Series C Financing to Advance Cancer Screening and Early Detection Programs

– AnchorDx announced the completion of a $40m Series C financing round.
– The round was led by OrbiMed and WuXi Huiying Investment.
– The company plans to use the new funds to accelerate the registration and commercialization of its NGS-based products for single-cancer, multi-cancer, and pan-cancer screening and early detection. The company also plans to deploy its technology to other major disease areas.

Source
Biotechnology Health Care Health Diagnostics Life Science North America

Micronoma Closes $3.5M Convertible Debt Financing Round

– Micronoma is a San Diego, Calif.-based cancer detection biotech company that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology.
– The company closed a $3.5m convertible debt financing round.
– Backers included SymBiosis, LLC and The Seerave Foundation.
– The investments bring the company’s total amount of funding to $6.5m since the first seed round six months ago.

Source
Biopharma Biotechnology Life Science Machine Learning Manufacturing North America

AbSci Announces Strategic Investment

– AbSci announced a strategic equity investment by Merck Global Health Innovation Fund.
– Merck GHI is a fund of Merck Research Laboratories.
– AbSci is a leading synthetic biology company that translates ideas into drugs with a revolutionary platform technology that reinvents the biopharmaceutical drug discovery process.

Source
Biotechnology North America

AmacaThera Announces Close of Oversubscribed Series A Financing to Advance a Novel Post-Operative, Nonopioid Pain Therapy in Clinical Trials

– AmacaThera announced the close of an oversubscribed $10.3m Series A financing to support development of AMT-143, the company’s lead clinical asset, and pipeline expansion.
– The Series A round was led by Lumira Ventures and includes a global investor syndicate of existing investors, Viva BioInnovator and Sprout BioVentures, as well as new investors, BDC Capital Women in Technology (WIT) Venture Fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures, and MaRS IAF.

Source
1 2 3 4 5
Crunchbase icon

Content report

The following text will be sent to our editors: